Significance of the preoperative neutrophil-to-lymphocyte ratio in the prognosis of patients with gastric cancer

Table 3 Univariate and multivariate survival analysis results

Clinicopathological feature	Univariate-analyzed P value	Multivariate analysis
		P value	HR (95%CI)
Gender	0.611
Male
Female
Age	0.000	0.096
< 65 yr			0.774 (0.573-1.046)
≥ 65 yr			1.000
Tumor size	0.000	0.122
< 5 cm			0.784 (0.576-1.067)
≥ 5 cm			1.000
Differentiation degree	0.108
Middle and high differentiation
Low differentiation
T staging	0.000	0.583
T1		0.898	0.879 (0.122-6.338)
T2		0.579	0.797 (0.358-1.776)
T3		0.170	0.739 (0.480-1.138)
T4			1.000
N staging	0.000	0.080
N0		0.303	0.622 (0.252-1.535)
N1		0.910	1.037 (0.556-1.934)
N2		0.091	0.678 (0.433-1.063)
N3			1.000
TNM staging	0.000	0.008
Stage I		0.030	0.134 (0.022-0.822)
Stage II		0.004	0.387 (0.204-0.735)
Stage III			1.000
Platelet counting	0.382
< 300 × 109/L
≥ 300 × 109/L
CEA	0.000	0.547
< 5 ng/mL			0.912 (0.675-1.231)
≥ 5 ng/mL			1.000
NLR	0.000	0.003
< 3.5			0.626 (0.460-0.852)
≥ 3.5			1.000

NLR: Neutrophil-to-lymphocyte ratio; CEA: Carcinoembryonic antigen; HR: Hazard ratio.